



# Making Lives Safer Through **NANOTECHNOLOGY**

PREVENTING THE SPREAD OF PATHOGENS


# Forward-Looking Statement

This presentation contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; expectations regarding industry trends, including with respect to the antimicrobial surface and coating market, overall market growth rates and the Company's growth rates and growth strategies; that microbe repellent technology is a promising, high-growth industry; the use of available funds; the performance of the Company's business and operations; the Company's expectations regarding revenues, expenses and anticipated cash needs; the intention to grow the Company's business and operations; the expected timing and completion of the Company's near-term objectives; laws and regulations and any amendments thereto applicable to the Company; the Company's competitive advantages and business strategies; the Company's future product offerings, including potential new applications (i.e. catheters) and new formulations (i.e. spray); the Company's research and development initiatives and expected results thereof; the Company's growing patent portfolio; the Company entering into distribution, manufacturing and other business relationships, in Canada, the United States, and globally; the potential of the Company's technology to protect against the spread of pathogens on surfaces through repelling bacteria and viruses that come in contact with its surface; that the Company's technology will bring significant value in controlling the spread of surface borne infectious diseases; trends regarding healthcare-acquired infections; proprietary REPELWRAP™ film could be used on high-touch surfaces such as bed rails, doorknobs, and medical devices to help prevent pathogen transmission; the Company's nanotechnology has the potential to be applied to other types of surfaces and materials – such as catheters which could significantly help reduce blockages caused by bacterial colony and/or blood clot formation in long-use catheters and that underserved markets like this offer potentially future upside, if the Company can successfully adapt their technology; the Company's intention to initially target REPELWRAP™ film towards healthcare settings and high traffic public touchpoints; that as the Company continues its product development, we may see it used to protect surfaces in other high traffic places like the transportation, education, sports and entertainment sectors; the growing global commitment to reduce the spread of pathogens; the development of the Company's spray nanotechnology, which could be easier to apply to many surfaces and expand potential market applications; the Company's organic growth strategy and expansion strategy; line extensions for REPELWRAP™ film; further development of core technology into additional applications (i.e. catheters); expansion into vertical markets; licensing of additional nanotechnology formulations and/or complementary products that reduce pathogen spread; potential licensing, M&A and partnerships within the infectious disease space; and that REPELWRAP™ film will provide additional protection to current disinfecting practices to control the spread of pathogens.

Important factors that could cause future results to differ materially from those anticipated in these forward-looking statements include: product candidates only being in formulation/reformulation stages; limited operating history, no revenues and uncertainty around additional financing; negative cash flow history; no production history and lack of revenues from sales; no history of manufacturing or distribution; highly competitive industry; satisfying the terms of the License Agreement, Spray License Agreement and Collaborative Research Agreement between the Company and McMaster University and maintaining licenses in good standing; inability of McMaster University to satisfy the terms under the License Agreement, Spray License Agreement and Collaborative Research Agreement; completion of scale-up and development of a commercial product; research and development activities; reliance on grant funding; limited number of products; dependence on collaborative partners, licensors and others; changes and restrictions due to legal and regulatory requirements; dependence on each product's acceptance in the market; possibility of smaller market opportunities than anticipated; increasing regulatory and compliance costs for public companies; global economic instability; product liability claims and lawsuits; system failures; reliance on management and loss of key employees or inability to hire key personnel; limited experience of senior management in managing a public company; fraudulent or illegal activity by employees, contractors and consultants; inability to effect service of process on some of the Company's directors and officers; management's efforts and abilities; potential conflicts of interest; inability to protect intellectual property rights; inability to secure patents or grow its patent portfolio; infringement on proprietary rights of third parties; risks related to forward-looking information; volatility of the market price of the Company's common shares; potential dilution of the common shares; lack of an active, liquid and orderly trading market for the common shares; failure of securities or industry analysts to publish research or publish inaccurate or unfavourable research about the Company; inability or unwillingness to pay dividends; exchange rate fluctuations between the Canadian dollar and the U.S. dollar; effect of COVID-19 public health crisis or another global health pandemic; use of available funds; effect of general economic and political conditions; internal controls; and other risk factors set forth in the Company's final prospectus dated January 31, 2023 under the heading "Risk Factors" and other filings, publicly available through the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval (SEDAR) at [www.sedarplus.ca](http://www.sedarplus.ca). The reader is urged to refer to the Company's prospectus and other filings, publicly available through SEDAR at [www.sedarplus.ca](http://www.sedarplus.ca) for a more complete discussion of such risk factors and their potential effects. Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any Forward-looking statements contained in this presentation are expressly qualified in their entirety by this cautionary statement.

While the information contained in this presentation is believed to be accurate, the Company expressly disclaims any and all liability for any losses, claims or damages of whatsoever kind based upon the information contained in, or omissions from, this presentation or any oral communication transmitted in connection therewith. In addition, none of the statements contained in this presentation are intended to be, nor shall be deemed to be, representations or warranties of the Company. Where the information is from third-party sources, the information is from sources believed to be reliable, but the Company has not independently verified any of such information contained herein.

This presentation is not, and under no circumstances is to be construed as, a prospectus, an offering memorandum, an advertisement or a public offering of securities. Under no circumstances should the information contained herein be considered an offer to sell or a solicitation of an offer to buy any securities.



FendX is a nanotechnology company focused on **reducing the spread of pathogens to keep surfaces safe from contamination.**

Film nanotechnology has repelling properties that prevent adhesion of bacteria, viruses, and liquid<sup>1,2</sup>

Spray nanotechnology has bifunctional properties that repel to prevent adhesion of bacteria and viruses and kill any residual bacteria and viruses<sup>3</sup>

**>99%**

Film: Instant reduction of adhesion of Covid-19 like virus<sup>1</sup>

**>99%**

Spray: Instant reduction of adhesion of Covid-19 like virus and bacteria<sup>3</sup>

**>99.7%**

Spray: Reduction in bacterial growth after 8 hours<sup>3</sup>

Sources:

1. ACS Appl. Mater. Interfaces 2022, 14, 11068-11077; 2. ACS Nano. 2020 Jan 28, 14 (1) 454-465; 3. ACS Applied Materials and Interfaces, 2023, 15, 16253-16265.

# Our Nanotechnology in the Media



“Researchers have developed a self-cleaning plastic wrap that repels bacteria and could be used to prevent the transfer of antibiotic resistant superbugs, and other forms of dangerous bacteria.” [Read more](#)



“Bacteria-Fighting RepelWrap Wins 'Create the Future' Design Contest” [Read more](#)



“Scientists engineer self-cleaning surface that can repel dangerous bacteria.” [Read more](#)



“Virus-Repelling Plastic Wins Top Prize in ‘Create the Future’ - Contest in 2020

“Self-cleaning surface that instantly repels viruses and bacteria – preventing the spread of superbugs”

“Technology could reduce the spread of COVID-19”

[Read more](#)



“The ultimate non-stick coating.”  
- McMaster University Brighter World  
[Read more](#)



“The treated material also ideal for food packaging, where it could stop the accidental transfer of bacteria, such as E. coli, Salmonella and listeria from raw chicken, meat and other foods.” [Read more](#)



“New self-cleaning wrap repels bacteria.”  
[Read more](#)

# Investment Highlights

ANTIMICROBIAL COATING MARKET ESTIMATED TO REACH \$7.6 BILLION BY 2025<sup>1</sup>



## Unique Disruptive Technology

- Award-winning nanotechnology with instant repelling properties against bacteria, viruses and liquids
- Spray formulation repels and kills bacteria and viruses
- Building a robust patent portfolio



## Numerous Potential Applications in Healthcare and Other Industries

- Potential applications in healthcare, transportation, sports and entertainment, schools and offices



## Experienced Team

- Strong leadership team with a proven track record building organizations, capital markets and bringing products to market



## Global Need for Innovative Products to Combat the Spread of Pathogens and Viruses

- > 99,000 deaths annually in the U.S from healthcare-acquired infections with direct medical costs at least \$28.4 billion each year<sup>2</sup>
- Timely opportunity - recent COVID-19 pandemic highlighted public awareness of virus transmission



## Accelerating Development

- Agreement in place with globally recognized coatings and films manufacturer to assess and create intermediate-sized REPELWRAP™ films for testing

Sources: 1. Future Markets Technology Report, Advanced Microbial Coatings, 2023

2. CDC, <https://www.cdc.gov/policy/polaris/healthtopics/hai/index.html>,

# Effective Pathogen Control Requires Innovative Solutions

## THE PROBLEM

- Infections continue to be responsible for high morbidity and mortality rates<sup>1</sup>
- Global health protection agencies seeking innovative solutions to reduce the spread of life-threatening pathogens
- > 99,000 of deaths annually in U.S.<sup>2</sup>
- Significant socio-economic impact costs of \$12.4B and direct medical costs of at least \$28.4 billion annually in the U.S.<sup>3</sup>

## CHALLENGES WITH EXISTING SOLUTIONS

- Existing surface coatings and protective films require pathogens to stick to the surface to be inactivated and can take hours
- Regular disinfectant cleaning surfaces only provides short-term protection
- Growing microbial resistance to existing metal and ion-based disinfectants<sup>3,4</sup>


Sources:

1. Future Markets Technology Report, Advanced Microbial Coatings, 2023

2. [Healthline](#)

3. CDC, <https://www.cdc.gov/policy/polaris/healthtopics/hai/index.html>

4. Metal Resistance and Its Association With Antibiotic Resistance, Advances in Microbial Physiology, Volume 70, 2017



Healthcare-acquired infections are one of the top 10 frequent causes of death globally<sup>1</sup>

# Surfaces and Objects Can Spread Pathogens

PATHOGENS EXIST IN CRITICAL AND EVERYDAY ENVIRONMENTS ON **HIGH-TOUCH SURFACES**



HEALTHCARE ENVIRONMENTS



TRANSPORTATION



SPORTS & ENTERTAINMENT



SCHOOLS




OFFICES

DOORKNOBS, HANDRAILS & MORE

COUNTERTOPS & TABLES

LIGHT SWITCHES

FLUSH HANDLES




ELEVATOR PANELS & BUTTONS

IV POLES

TROLLEYS & EQUIPMENT

SWITCHES & PUSH PLATES





# REPELWRAP™ Film

## First product in development to protect against contamination on surfaces

Award-winning REPELWRAP™ film instantly repels bacteria, viruses, blood and liquids.

Dunmore International Corp. (“Dunmore”), a Steel Partners Holdings L.P. (NYSE:SPLP) operating company are creating intermediate-sized films for testing.


Committed to further development and testing with the intention of developing a commercial product.



# REPELWRAP™ Film, a Patented Innovation

Our patent-pending nanotechnology works by combining micro- and nano-layers and thermal shrinking to create surfaces with repelling properties that prevent the adhesion of bacteria, viruses and liquids.

High-surface tension (e.g., water) and low-surface tension (e.g., oil) liquids form droplets when they come in contact with the nano-surface.



Schematic diagram illustrating the manufacturing process of REPELWRAP™ film.



## BUILDING ROBUST PATENT PORTFOLIO, LICENSED FROM MCMASTER:

- National filing of International PCT Application No. **PCT/CA2020/05076**, entitled **OMNIPHOBIC SURFACES WITH HIERARCHICAL STRUCTURES, AND METHODS OF MAKING AND USES THEREOF** filed in Canada, China, Europe, Hong Kong, U.S., and Japan.
- PCT Patent Application Number **PCT/CA2022/051249**, entitled **FLUORINE-FREE SUPERHYDROPHOBIC SURFACES, METHODS OF MARKEING AND USES THEREOF**
- PCT Patent Application Number **PCT/CA2022/051259**, entitled **METHODS OF MAKING OMNIPHOBIC MATERIALS WITH HIERARCHICAL STUCTURES AND USES THEREOF**


# REPELWRAP™ Film Proven to Prevent the Spread of Pathogens

## DURABILITY

Holds repelling properties under strain and while conforming to different form factors (bent or unbent)<sup>2</sup>



Maintains robust repelling properties after being subjected to various physical and mechanical forces<sup>2</sup>



**TREATED\***  
 Research has shown REPELWRAP™ film effectively reduced biofilm formation of World Health Organization-designated priority pathogens.



**UNTREATED\***

## EFFECTIVENESS

**>99%**

Reduction in adhesion of Covid-19 like strains<sup>1</sup>

**>87%**

Reduction in colony formation of MRSA<sup>2</sup>



Surface remains free after touching with E. coli<sup>2</sup>




Successfully repels blood<sup>2</sup>

\*For illustration purposes  
 Sources: 1. ACS Appl. Mater. Interfaces 2022, 14, 11068-11077; 2. ACS Nano. 2020 Jan 28, 14 (1) 454-465

# How Our Nano-Surfaces Work

When a contaminated hand touches a surface covered with our nanotechnology, the contamination stays on the hand and does not transfer to the surface.

Coated with Nanotechnology



Uncoated

Schematic illustration comparing person-to-person transfer of viruses from common high touch surfaces.

# Competitive Landscape: Film and Spray Nanotechnology

	FendX Film Nanotechnology*	FendX Spray Nanotechnology*	Liquid Disinfectants	Metal-Containing** and Photo-Activated Films
Surface repels bacteria, viruses, blood and liquids	+++	+++	-	-
Kills bacteria and viruses	-	+++	+++	+++
Effective pathogen control	+++	+++	+	++
Instantly effective	+++	+++	+++	+
24/7 protection	+++	+++	-	+++
Does not require regular cleaning and maintenance	+++	+++	-	++
Self-cleaning	+++	+++	-	++
Does not promote bacterial resistance	+++	+++	+	+



\*Based on McMaster testing of REPELWRAP™ film lab prototype (ACS Appl. Mater. Interfaces 2022, 14, 11068-11077; ACS Nano. 2020 Jan 28, 14 (1) 454-465; 3. ACS Applied Materials and Interfaces, 2023, 15, 16253-16265.)

\*\*Silver, copper, zinc


# Antimicrobial Coating Market: A Significant Opportunity for Our Nanotechnology

Global antimicrobial coating market estimated to reach \$7.6 billion in 2025<sup>1</sup>.

Medical and healthcare is the largest segment of the antimicrobial coatings market



Total Global Revenues for Antimicrobial Coatings (millions USD)



Sources: 1. Future Markets Technology Report, Advanced Microbial Coatings, 2023

# Pipeline & Growth Strategy

## ORGANIC GROWTH

- Line extensions of REPELWRAP™ film
- Further development of core technology into additional applications (i.e., catheters)
- Development of spray nanotechnology

## GROWTH STRATEGY

- Assess opportunities for the following:
- Assess applications for our nanotechnology beyond healthcare
  - Expand into the U.S. and other markets
  - Explore potential licensing opportunities of products complementary to current focus



# Catheter Product Development – The Next Opportunity

- Will be commencing a development program to coat medical catheters with FendX's nanotechnology
- In early research, McMaster has shown coating plastic similar to what is used in catheters reduces MRSA and P. aeruginosa adhesion by 98.5%
- With blood, reduces staining by 95% and suppresses thrombin formation to background levels<sup>3</sup>



## Failure of long-term indwelling catheters is commonly caused by blood clots and/or bacterial biofilm formation

- The global urinary catheter market was \$1.2 Billion USD in 2019 and projected to reach \$2.2 billion USD in 2027<sup>1</sup>
- The global hemodialysis implantable catheter market is \$787 million USD in 2022 and estimated to be \$1.2 billion USD in 2030<sup>2</sup>

*“This work stands to hold high probability within biomedical systems as a means to prevent fouling, thus improving performance.”<sup>3</sup>*

#### Sources:

1. <https://www.alliedmarketresearch.com/indwelling-catheters-market-A07452#:~:text=The%20global%20indwelling%20catheters%20market%20size%20accounted%20for,a%20CAGR%20of%209.1%25%20from%202020%20to%202027.>
2. <https://www.globenewswire.com/en/news-release/2022/07/13/2479187/0/en/Hemodialysis-Catheters-Market-Size-to-Surpass-USD-1-214-Million-by-2030-Fueled-By-Growing-Prevalence-of-Chronic-Kidney-Disorders.html>
3. Small. [www.small-journal.com](http://www.small-journal.com), 2022, 18, 2108112.

# Expanded Nanotechnology Platform with a Spray Formulation that Repels and Kills Bacteria and Viruses

## Development-stage nano-spray coating

- Reduced adhesion of MRSA by 99.9% and 98% for Phi6 (Covid-19 like virus)<sup>1</sup>
- Plastic gloves sprayed with the nanotechnology reduced transfer of MRSA and the Covid-19 like virus by 99.99% after only one touch<sup>1</sup>
- Reduced biofilm formation by 99.98% for both MRSA and *P. aeruginosa*<sup>1</sup>




**An important addition to our current nanotechnology as it could be easier to apply to many surfaces and expand potential market applications**

## FILED PATENT LICENSED FROM MCMASTER:

- US Provisional Patent Application No **63/415078**, entitled **OMNIPHOBIC ANTIMICROBIAL MICROPARTICLES AND COMPOSITIONS THEREOF**

Source: 1 ACS Applied Materials and Interfaces, 2023, 15, 16253-16265.


# Key Achievements and Objectives



# Efficient Operating Model

COST-EFFECTIVE STRATEGY TO  
MANUFACTURE AND SELL FENDX  
PRODUCTS

Intention to leverage the expertise of contract manufacturers and distributor to efficiently manage FendX capital expenditures



## Manufacturers

Establish partnerships to manufacture REPELWRAP™ film and other products for distribution in Canada, U.S. and other global markets



## Sales Distributors

Secure partnerships to sell REPELWRAP™ film in Canada, U.S. and other global markets

Goal is to work with companies that have reach and frequency to sell in a broad range of high touch point markets

# Proven Team Management



**Dr. Carolyn Myers MBA, PhD**  
President, CEO & Director

- Principal of BioEnsemble LLC, assisting start-ups and small pharma companies in developing their business strategy and planning
- Vice President International Business Development and Alliance Management at Allergan PLC (market cap \$83 Bn, 2017, now Abbvie),
- President of Dey Laboratories and President of Mylan Technologies Inc. (market cap \$9.2 Bn, 2011, now Viatrix Inc.)
- Senior management at Pharmacia Corporation (now Pfizer)
- Director Mayne Pharma Group Ltd. (ASX:MYX) and Hyloris Pharmaceuticals SA (BR:HYL)



**Andrea Mulder BPHE, MBA**  
COO

- Over 25 years of pharma/biotech expertise in marketing and sales leadership
- Led the launches of over 10 pharmaceutical products in Canada
- Significant therapeutic knowledge in infectious disease, immunology, neurology, respiratory and oncology
- Member of Global and/or Canadian leadership teams at: Eisai, Ipsen, Pfizer, GlaxoSmithKline, Roche and Johnson and Johnson



**Rose Zanic CPA, CA**  
CFO & Corporate Secretary

- Over 25 years of capital markets and corporate finance expertise
- Significant experience advising Canadian public companies with financing, M&A transactions and providing public company administration.
- Previously Senior Vice-President, Corporate Finance at Wolverton Securities Ltd.
- Director and/or officer of several Canadian publicly listed companies
- Member of the TSX Venture Exchange BC Local Advisory Committee

# Board of Directors

## **Dr. Carolyn Myers MBA, PhD**

President, CEO & Director

- Principal of BioEnsemble LLC, assisting start-ups and small pharma companies in developing their business strategy and planning.
- Vice President International Business Development and Alliance Management at Allergan PLC,
- President of Dey Laboratories and President of Mylan Technologies Inc.
- Senior management at Pharmacia Corporation (now Pfizer)
- Director Mayne Pharma Group Ltd. and Hyloris Pharmaceuticals SA

## **Stephen Randall CPA, CGA**

Independent Board Member  
& Audit Committee Chair

- Senior financial manager and Director with over 40 years' experience.
- Served in senior financial roles with both private, publicly traded and start-up companies in the manufacturing, telecommunications, technology, and medical device sectors.
- Former Board Member, CFO and Corporate Secretary of Titan Medical Inc (TSX: TMD and NASDAQ: TMDI)

## **Pierre Soulard B.C.L., LLB, LLM**

Independent Board Member

- Chief Legal Officer of CoinSmart (NEO: SMRT)
- Former partner, at Miller Thomson, a leading Canadian law firm.
- Focused on securities law, corporate finance, mergers and acquisitions and corporate governance for a wide range of national and international issuers and investors.

# Share Structure

CSE: FNDX / AS OF SEPTEMBER 30, 2023

Common Stock	52,991,606
Stock Options	2,741,667
Warrants	15,905,807
Bonus Shares <sup>1</sup>	4,150,000
Fully-Diluted	75,789,080

<sup>1</sup> Shares issuable upon satisfaction of certain development milestones.

# THANK YOU!

Reach out to us with any questions.

[investor@fendxtech.com](mailto:investor@fendxtech.com) / [fendxtech.com](https://fendxtech.com)